SCHEMBL3484782

SCHEMBL3484782

Nc1ccc(Oc2ccc3cc[nH]c3c2)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
SCN9A Q15858 1/20 0.47
AHR P35869 3/20 0.44
CMA1 P23946 1/20 0.44
PDE7A Q13946 1/20 0.42
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
RHEB Q15382 4/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
HTR6 P50406 1/20 0.37
MAOA P21397 1/20 0.37
CSNK2A1 P68400 1/20 0.37
TYR P14679 1/20 0.37
EGFR P00533 1/20 0.36
PNLIP P16233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483906 0.89 AHR (0.44) SCN9AAHRPDE7AHTR2ASLC6A4
SCHEMBL3485196 0.78 KDM4E (0.58) MEN1POLBKMT2APDE7AHTR2A
SCHEMBL3484765 0.78 KDM4E (0.59) MEN1POLBMAPK1KMT2ASCN9A
SCHEMBL1913888 0.77 LMNA (0.62) SCN9APDE7AHTR2ASLC6A4LMNA
SCHEMBL4318630 0.76 PDE7A (0.63) MEN1KMT2APDE7AHTR2ASLC6A4
SCHEMBL11460671 0.75 HTR2A (0.63) PDE7AHTR2ASLC6A4PNLIPMPO
SCHEMBL10962941 0.75 MAPT (0.55) MEN1KMT2APDE7AHTR2ASLC6A4
SCHEMBL94619 0.74 AHR (0.56) MEN1POLBMAPK1KMT2AAHR
SCHEMBL29670282 0.74 AHR (0.56) MEN1POLBMAPK1KMT2AAHR
SCHEMBL7184491 0.73 PDE7A (0.53) MEN1MAPK1KMT2APDE7AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 MEN1 2063/4885POLB 4222/4885MAPK1 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.